17,261 trials
Breast Cancer
Primary: Cardiac Saftey — 68; 67; 66; 65 percentage of LVEF
Gout Flares
Primary: Number of Gout Flares Per Subject — 3.02; 2.45 flares — p=0.1356
Breast Cancer
Primary: Pathologic Complete Response Rate (pCR) — 27 participants
Postoperative Cognitive Dysfunction
Primary: The Time From the End of Anesthesia to Extubation — 329.0; 636.0 second
Non-Small Cell Lung Cancer
Primary: Objective Response Rate (Part I) — 4; 20; 1; 0 Participants
Postoperative Pain · Acute Pain
Primary: Pharmacokinetic Profile of Serum Concentrations of Tapentadol After a Single Dose of Tapentadol Oral Solution in Adolescents (Age 12 to Less Than 18 Years). — 23.2…
Recurrent Endometrial Carcinoma
Primary: Progression-free Survival Greater Than 6 Months — 31; 21 participants
Meningococcal Vaccine · rLP2086 · Repevax
Primary: Percentage of Participants Achieving Prespecified Criteria for the Concomitant Antigen — 99.4; 99.4; 100.0; 100.0 percentage of participants
Vaccines · Meningococcal Vaccines
Primary: Geometric Mean Titer (GMT) of Human Papillomavirus (HPV) Antigens — 451.8; 550.3; 892.9; 1084.3 titer
Mantle Cell Lymphoma
Primary: Number of Participants Achieving Complete Remission (CR) (Including Unconfirmed CR [CR(u)]) or Partial Remission (PR) — 19; 8 participants
Amyotrophic Lateral Sclerosis
Primary: The Proportion of Responder Patients in the Two Treatment Groups According the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS)-R Slope. — 13; 6 participants
Adenocarcinoma of the Pancreas · Recurrent Pancreatic Cancer · Stage IV Pancreatic Cancer
Primary: Survival Rate — 5 participants
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Adult Acute Myeloid Leukemia in Remission · Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Primary: Proportion of Patients With Clinical Response — 0.32; 0.27; 0.46; 0.17 Proportion of patients
Ischemic Stroke
Primary: Frequency of Symptomatic Hemorrhagic Transformation Safety of iv Rt-PA in Wake up Stroke Patients — 0 cases.
Hepatitis C Virus
Primary: Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12) — 78.6; 58.8; 100.0; 86.7 percentage of…